newratings.com  Jul 20  Comment 
WASHINGTON (dpa-AFX) - Medidata Solutions (MDSO) revealed a profit for its second quarter that rose compared to the same period last year. The company said its bottom line climbed to $13.52 million, or $0.24 per share. This was up from $12.08...
Benzinga  Apr 26  Comment 
Medidata (NASDAQ: MDSO) revealed that Christian Hebenstreit has joined it as managing director of EMEA, which consisted of Europe, the Middle East and Africa. According to the company, Christian would report to its chief operating officer, Mike...
newratings.com  Apr 21  Comment 
WASHINGTON (dpa-AFX) - Medidata Solutions Inc. (MDSO) said that its full year 2016 guidance provided on February 10, 2016 remains unchanged. Adjusted non-GAAP net income, which primarily excludes the impact of stock-based compensation, non-cash...
newratings.com  Apr 21  Comment 
WASHINGTON (dpa-AFX) - Medidata Solutions (MDSO) announced a profit for its first quarter that gained ground from last year. The company said its bottom line advanced to $14.11 million, or $0.25 per share. This was higher than $9.22 million, or...
Motley Fool  Feb 10  Comment 
Investors may want to look beyond the top-line miss and focus on future growth.

Medidata Solutions (NASDAQ:MDSO) sells a software platform called Medidata Rave that helps biotech and pharmaceutical companies enhance the efficiency of their clinical development processes.[1] It achieves this by integrating electronic data capture (EDC) with a clinical data management system (CDMS) in a single product.
Error creating thumbnail
Medidata Rave is a comprehensive platform that replaces traditional paper-based methods of capturing and managing clinical data.
The company also sells a protocol authoring tool (Medidata Designer), a grant management system (Medidata Grant Manager) and a CRO contracting platform (Medidata CRO Contractor). In 2007, 2008 and the first quarter of 2009, the company's top five customers by revenue were Johnson & Johnson, AstraZeneca, Amgen, Astellas Pharma and Takeda Pharmaceutical.[1]

Medidata's initial public offering (IPO) of stock is scheduled for 18 June 2009. It plans to sell 6.3 million shares at between $11 and $12 per share. In 2008, the company had $106 million in total revenues, up 67.9% from $63.0 million in 2007. However, it still made a net loss of $18.3 million, down 22.8% from the $23.7 million net loss made in 2007.[2] In the same year, 69% of revenues came from customers in the United States, 21% from Europe and 10% from Asia (including Australia). In the first quarter of 2009, the company had $33.6 million in total revenues, up 60.2% from $21.0 million in the same quarter of the 2008.[2] It also had $1.7 million in net income, up 120% from the $8.6 million net loss made in 2007. Existing investors in the company include Insight Venture Partners (33.9%), chief executive officer and chairman Tarek Sherif (9.0%), president and director Glen M. de Vries (9.0%) and Milestone Venture Partners (7.6%).


  1. 1.0 1.1 Business, 2009 MDSO S-1/A
  2. 2.0 2.1 Selected Consolidated Financial Information, 2009 MDSO S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki